IRIS
SPAGNUOLO, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.735
AS - Asia 3.037
NA - Nord America 2.150
SA - Sud America 722
AF - Africa 61
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.713
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 2.260
US - Stati Uniti d'America 2.054
SG - Singapore 1.070
CN - Cina 974
BR - Brasile 593
RO - Romania 339
HK - Hong Kong 329
VN - Vietnam 315
SE - Svezia 258
IT - Italia 235
DE - Germania 172
FR - Francia 150
GB - Regno Unito 100
IN - India 78
AR - Argentina 59
FI - Finlandia 54
CA - Canada 43
IQ - Iraq 39
ID - Indonesia 35
MX - Messico 35
AT - Austria 34
BD - Bangladesh 33
PL - Polonia 30
TR - Turchia 28
JP - Giappone 26
ZA - Sudafrica 24
NL - Olanda 23
ES - Italia 21
EC - Ecuador 20
CO - Colombia 15
IE - Irlanda 15
PK - Pakistan 14
PH - Filippine 13
SA - Arabia Saudita 12
UZ - Uzbekistan 12
LT - Lituania 10
TN - Tunisia 10
VE - Venezuela 9
AE - Emirati Arabi Uniti 8
NP - Nepal 8
CL - Cile 7
CZ - Repubblica Ceca 7
MY - Malesia 7
UA - Ucraina 7
DO - Repubblica Dominicana 6
MA - Marocco 6
PY - Paraguay 6
UY - Uruguay 6
AU - Australia 5
BE - Belgio 5
KE - Kenya 5
OM - Oman 5
AZ - Azerbaigian 4
DZ - Algeria 4
IL - Israele 4
PE - Perù 4
BB - Barbados 3
BH - Bahrain 3
CI - Costa d'Avorio 3
HN - Honduras 3
CH - Svizzera 2
EU - Europa 2
GE - Georgia 2
IR - Iran 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
KZ - Kazakistan 2
NG - Nigeria 2
PA - Panama 2
PS - Palestinian Territory 2
PT - Portogallo 2
RS - Serbia 2
SC - Seychelles 2
SV - El Salvador 2
TH - Thailandia 2
AL - Albania 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GY - Guiana 1
HR - Croazia 1
JO - Giordania 1
KI - Kiribati 1
LB - Libano 1
LY - Libia 1
MD - Moldavia 1
MT - Malta 1
NI - Nicaragua 1
NO - Norvegia 1
QA - Qatar 1
SI - Slovenia 1
SN - Senegal 1
SR - Suriname 1
SY - Repubblica araba siriana 1
Totale 9.713
Salva come PNG Salva come JPEG
Città #
Singapore 543
Moscow 455
Dallas 337
Hong Kong 325
Ashburn 290
San Jose 235
Shanghai 164
New York 154
Hefei 140
Beijing 136
Lauterbourg 121
Ho Chi Minh City 106
Lawrence 95
Princeton 95
Hanoi 74
Milan 72
Los Angeles 69
Munich 55
São Paulo 47
Boardman 44
Nuremberg 42
Orem 40
Helsinki 34
Denver 31
Warsaw 29
Chennai 26
Tokyo 26
London 23
Santa Clara 23
Guangzhou 22
Frankfurt am Main 20
Da Nang 19
Brooklyn 18
Vienna 18
Houston 17
Manchester 17
Atlanta 16
Baghdad 16
Montreal 16
Stockholm 16
Dublin 15
Poplar 15
Council Bluffs 14
Rome 14
Shenzhen 14
Brasília 13
Johannesburg 13
Rio de Janeiro 13
Toronto 13
Amsterdam 12
Ankara 12
Curitiba 12
Falkenstein 12
Turku 12
Washington 12
Biên Hòa 11
Phoenix 11
Seattle 11
Tashkent 11
Mexico City 10
Barnet 9
Chicago 9
Guayaquil 9
Haiphong 9
Belo Horizonte 8
Porto Alegre 8
Pune 8
Querétaro 8
Sorocaba 8
Boston 7
Goiânia 6
Hải Dương 6
Lappeenranta 6
Madrid 6
Mumbai 6
New Delhi 6
Quanzhou 6
Salvador 6
San Francisco 6
Brussels 5
Buenos Aires 5
Campinas 5
Charlotte 5
City of London 5
Columbus 5
Erbil 5
Ha Long 5
Hangzhou 5
Istanbul 5
Jakarta 5
Montevideo 5
Monza 5
Quezon City 5
Saint Louis 5
Santos 5
São Bernardo do Campo 5
The Dalles 5
Vittoria 5
Baku 4
Can Tho 4
Totale 4.516
Salva come PNG Salva come JPEG
Nome #
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment 249
Monkeypox in a patient with undifferentiated connective tissue disease 249
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 180
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 166
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 151
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 124
Cardiac implantable electronic device infections: impact of initiation of antimicrobial treatment before or after device removal on microbiological yield 117
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 115
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 112
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study 110
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 109
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 109
Achieving virological control in pan-resistant HIV-1 infection: A case series 108
Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV 107
Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting 106
Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1-infected patients 103
Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals 102
Implementation of recombinant anti-herpes zoster vaccination in people living with HIV: a single-center experience 101
Bictegravir 99
Sexually transmitted infections in men who have sex with men with tenofovir/emtricitabine- or cabotegravir-resistant HIV 99
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 96
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study 93
HIV-DNA undetectability during chronic HIV infection: Frequency and predictive factors 93
Long-term outcome in a person with pandrug-resistant HIV: the added value of a multidisciplinary approach 90
Disseminated Mycobacterium chimaera infection favoring the development of Kaposi’s sarcoma: a case report 89
Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection 89
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 89
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 88
Impact of Respiratory Syncytial Virus (RSV) on adult haematology oncology patients 88
Combination of High-Dose Daptomycin and Ceftriaxone for Cardiac Implantable Electronic Device Infections: A 10-Year Experience 88
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 87
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 86
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors 86
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression 85
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 85
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry 84
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study 84
Should we expect weight changes in people with HIV and a reported weight gain only by switching antiretroviral therapy? 83
Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study) 82
Inflammation burden score in multidrug-resistant HIV-1 infection 81
Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection 81
Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting 80
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: A Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 80
Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy 78
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 77
Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data 76
Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens 75
Darunavir for the treatment of HIV infection 75
Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance 74
Cardiovascular risk and dyslipidemia among persons living with HIV: A review 73
Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort 72
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 71
Non-Hodgkin lymphoma risk in adults living with HIV across five continents 71
Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization 69
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 68
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 67
Uberti Foppa C, Gaiera G, Nunzi E, Spagnuolo V Capitolo 101 Infezioni sistemiche in: Rugarli Medicina interna sistematica 67
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 67
Is shorter duration of antibiotic treatment feasible in patients with cardiac implantable electronic device infections undergoing device removal? A propensity-adjusted analysis of a 10-year retrospective cohort 67
Multidrug-resistant Mycoplasma genitalium urethritis: successful eradication with sequential therapy 66
An evaluation of cabotegravir for HIV treatment and prevention 65
Addressing late HIV presentation: the current knowledge and unmet needs 64
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 64
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium 63
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry 63
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 63
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 63
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine 62
All-Cause Mortality in People With Four-Class Drug-Resistant Human Immunodeficiency Virus: A Matched Cohort Analysis With Data From the PRESTIGIO Registry 61
Immune recovery and T cell subset analysis during effective treatment with maraviroc 59
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 59
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study 58
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy 58
Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. 58
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 58
Long-term suppression of viral replication in HIV-related lymphoma survivors: a case-control study 58
Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. 57
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort 57
Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study 56
Chronic hepatitis B and C virus infection and risk for non-hodgkin lymphoma in HIV-infected patients: A cohort study 56
Changes in Darunavir/r Resistance Score After Previous Failure to Tipranavir/r in HIV-1-Infected Multidrug-Resistant Patients 55
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era 54
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir 54
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test. 54
Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naive Patients With Recent Diagnosis of HIV-1 Infection 54
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting 54
LONG-TERM SURVIVAL AMONG HIV-1 INFECTED PATIENTS WITH AIDS AND NON AIDS RELATED MALIGNANCIES 54
Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply 52
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response 52
Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients 52
Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 52
Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV 52
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection 51
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens 51
Impact of analytical treatment interruption on burden and diversification of hiv peripheral reservoir: A pilot study 51
PRESTIGIO RING "a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests" 50
Mortality of HIV-infected patients with or without cancer: comparison with the general population in Italy 50
Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies 49
Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies 49
Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients. 49
Totale 8.057
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.709
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.709
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 1 0
2021/202278 0 0 0 18 9 9 2 13 7 4 9 7
2022/2023494 206 103 28 4 8 42 43 36 19 2 1 2
2023/2024463 11 18 81 31 49 121 6 43 1 4 27 71
2024/20252.159 194 25 42 64 89 164 661 167 250 132 114 257
2025/20266.678 523 497 480 903 538 243 615 581 1.941 357 0 0
Totale 9.964